Insulin-degrading enzyme is activated by the C-terminus of α-synuclein

Biochemical and Biophysical Research Communications

Volumn 466, Issue 2, 2015, Pages 192-195

  Sharma, Sandeep K ^a   Chorell, Erik ^a   Wittung Stafshede, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Amyloid; Insulin degrading enzyme; Parkinson's disease; Proteolysis; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID; INSULINASE; RECOMBINANT ENZYME;

ARTICLE; ATOMIC FORCE MICROSCOPY; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; CHEMISTRY; METABOLISM;

ALPHA-SYNUCLEIN; ENZYME ACTIVATION; INSULYSIN; MICROSCOPY, ATOMIC FORCE;

EID: 84942295055     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.09.002     Document Type: Article

References (25)

1. J.R. Brender, S. Salamekh, and A. Ramamoorthy Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective Acc. Chem. Res. 45 3 2012 454 462
2. A.S. DeToma, and et al. Misfolded proteins in Alzheimer's disease and type II diabetes Chem. Soc. Rev. 41 2 2012 608 621
3. S.A. Kotler, and et al. Differences between amyloid-beta aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease Chem. Soc. Rev. 43 19 2014 6692 6700
4. H.R. Patel, and et al. Search of Aggregation Pathways of IAPP and other amyloidogenic proteins: finding answers through NMR spectroscopy J. Phys. Chem. Lett. 5 11 2014 1864 1870
5. J.E. Galvin, and et al. Pathobiology of the Lewy body Adv. Neurol. 80 1999 313 324
6. B. Winner, et al., In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 108 (10) 4194-4199.
7. D. Eliezer, and et al. Conformational properties of alpha-synuclein in its free and lipid-associated states J. Mol. Biol. 307 4 2001 1061 1073
8. R.J. Kirschner, and A.L. Goldberg A high molecular weight metalloendoprotease from the cytosol of mammalian cells J. Biol. Chem. 258 2 1983 967 976
9. W.C. Duckworth, R.G. Bennett, and F.G. Hamel Insulin degradation: progress and potential Endocr. Rev. 19 5 1998 608 624
10. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, and et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels Science 316 5829 2007 1331 1336
11. L.J. Scott, and et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants Science 316 5829 2007 1341 1345
12. P. Steneberg, and et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells Diabetes 62 6 2013 2004 2014
13. W. Farris, and et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo Proc. Natl. Acad. Sci. U. S. A. 100 7 2003 4162 4167
14. Y. Shen, and et al. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism Nature 443 7113 2006 870 874
15. R.E. Llovera, and et al. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis J. Biol. Chem. 283 25 2008 17039 17048
16. M.B. de Tullio, L. Morelli, and E.M. Castano The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective Prion 2 2 2008 51 56
17. S.K. Sharma, and et al. Insulin-degrading enzyme prevents alpha-synuclein fibril formation in a nonproteolytical manner Sci. Rep. 5 2015 12531
18. I. Horvath, and et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation J. Am. Chem. Soc. 134 7 2012 3439 3444
19. H. Naiki, and et al. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1 Anal. Biochem. 177 2 1989 244 249
20. H. Im, and et al. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE J. Biol. Chem. 282 35 2007 25453 25463
21. Q. Guo, and et al. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme J. Mol. Biol. 395 2 2010 430 443
22. E. Malito, and et al. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme Biochemistry 47 48 2008 12822 12834
23. M. Nors Perdersen, and et al. Direct correlation between ligand-induced α-synuclein oligomers and amyloid-like fibril growth Sci. Rep. 5 2015 10422
24. S.F. Falsone, and et al. The neurotransmitter serotonin interrupts alpha-synuclein amyloid maturation Biochim. Biophys. Acta 1814 5 2011 553 561
25. M.B. de Tullio, and et al. Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic abeta peptide aggregates PLoS One 8 4 2013 e59113